Sign In
Last checked at 
21 May 2021 12:46
PDMR Dealing
Oxford, UK - 21 May 2021: Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed on 20 May 2021, that Dr. Kyriacos Mitrophanous, Chief Scientific Officer of the Group, exercised 25,000 LTIP (2014) options at nil cost, and sold all the resulting ordinary shares at 1096.9p per share. Following this transaction Dr. Kyriacos Mitrophanous continues to hold 147,476 options over ordinary shares.
The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares sold.
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
a) | Name | Kyriacos Mitrophanous | ||||
2. | Reason for the notification | |||||
a) | Position/status | Chief Scientific Officer
| ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford BioMedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code | Options over ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Exercise of options | ||||
c) | Currency | GBP - British pound | ||||
d) | Price(s) and volumes(s) |
| ||||
e) | Aggregated information - Aggregate volume
- Price
- Aggregated total
|
25,000
Nil
Nil | ||||
f) | Date of the transaction | 2021-05-19 | ||||
g) | Place of the transaction | Outside a trading venue | ||||
1. | Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA") | |||||
a) | Name | Kyriacos Mitrophanous | ||||
2. | Reason for the notification | |||||
a) | Position/status | Chief Scientific Officer
| ||||
b) | Initial notification/ amendment | Initial Notification | ||||
3. | Details of the Issuer | |||||
a) | Name | Oxford BioMedica plc | ||||
b) | LEI code | 213800S1GVQNXQ15K851 | ||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument
Identification code | Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 | ||||
b) | Nature of the transaction | Disposal | ||||
c) | Currency | GBP - British pound | ||||
d) | Price(s) and volumes(s) |
| ||||
e) | Aggregated information - Aggregate volume
- Price
- Aggregated total
|
25,000
£10.9694
£274,235.00 | ||||
f) | Date of the transaction | 2021-05-19 | ||||
g) | Place of the transaction | London Stock Exchange, Main Market (XLON) | ||||
-Ends-
For further information, please contact: |
|
Oxford Biomedica plc: Natalie Walter, Company Secretary |
Tel: +44 (0)1865 783 000 |
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a three year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 670 people. Further information is available at www.oxb.com
Follow the stocks
